Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 8/20 | 0.46 |
| ▸ | CA2 | P00918 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | SNCA | P37840 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | NT5E | P21589 | 2/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5169141 | 1.00 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1PKMHPGDMAPK1 | |
| SCHEMBL5873675 | 0.83 | MAPT (0.46) | L3MBTL1ALDH1A1PKMHPGDMAPK1 | |
| SCHEMBL5873678 | 0.83 | MAPT (0.46) | L3MBTL1ALDH1A1PKMHPGDMAPK1 | |
| SCHEMBL8323651 | 0.81 | MAPT (0.64) | MAPK1CA1CA2MAPTAPP | |
| SCHEMBL5430345 | 0.81 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1PKMHPGDMAPK1 | |
| SCHEMBL5169077 | 0.81 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1PKMHPGDMAPK1 | |
| SCHEMBL5430358 | 0.80 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1PKMHPGDMAPK1 | |
| SCHEMBL5430362 | 0.80 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1PKMHPGDMAPK1 | |
| SCHEMBL7899300 | 0.80 | POLB (0.55) | L3MBTL1ALDH1A1PKMHPGDMAPK1 | |
| SCHEMBL4994672 | 0.80 | POLB (0.55) | L3MBTL1ALDH1A1PKMHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815439-B2 | PYRROLO(2,3-B)PYRIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2004-11-09 | — | — | US | claimed |
| US-20040072836-A1 | Substituted aza-oxindole derivatives | HARRIS PHILIP ANTHONY (US) | 2004-04-15 | — | — | US | claimed |
| EP-1180105-B1 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2003-05-14 | — | — | EP | claimed |
| EP-1364212-B1 | THREE HYBRID ASSAY SYSTEM | GPC BIOTECH AG (DE) | 2011-02-02 | — | — | EP | disclosed |
| US-20070213403-A1 | TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS | FORSKARPATENT I SYD AB (SE) | 2007-09-13 | — | — | US | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-6815439-B2 | PYRROLO(2,3-B)PYRIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2004-11-09 | — | — | US | disclosed |
| US-20040072836-A1 | Substituted aza-oxindole derivatives | HARRIS PHILIP ANTHONY (US) | 2004-04-15 | — | — | US | disclosed |
| US-6624171-B1 | Useful as cyclin dependent kinase 11 inhibitors, for preventing/reducing the severity of epithelial cytotoxicity side-effects (e.g., alopecia, plantar- palmar syndrome, mucositis) induced by chemotherapy and/or radiation therapy | SMITHKLINE BEECHAM CORPORATION | 2003-09-23 | — | — | US | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | L3MBTL1 3106/4885ALDH1A1 3290/4885PKM 2084/4885 |
| US-20040072836-A1 | Substituted aza-oxindole derivatives | CCNI, AZI2, CDKN1A | L3MBTL1 3221/4885ALDH1A1 1625/4885PKM 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.